Sector Intelligence · Pharma · June 2026
Pharma Investment 2026
Pharmaceutical M&A activity, patent cliff dynamics, CRO and CDMO deal flow and private capital opportunities across UK and global pharma — for investors and family offices.
Market Data
The Numbers Shaping Pharma in 2026
$4.8bn
GTCR LLC's acquisition of Zentiva Group — one of the biggest US private equity-backed deals in European healthcare in 2025.
Source: Nelson Advisors/PwC analysis 2025
£300m
AstraZeneca's 2026 UK investment reversal, confirmed April 2026, reinforcing UK pharma manufacturing as a strategic government priority.
Source: ABPI April 2026; The Guardian April 2026
63%
Rise in global licensing and partnership payments in 2025 as pharma leaned more heavily on external collaborations to rebuild pipelines post-patent cliff.
Source: Cushman & Wakefield Life Sciences Update February 2026
31.7%
Projected CAGR of AI in pharmaceuticals from 2025 to 2030 — from $3.8 billion to $15.2 billion.
Source: BCC Research November 2025
Investment Landscape
The Pharma Market in 2026
The patent cliff — the expiry of blockbuster drug patents driving revenue loss for major pharmaceutical companies — is the defining structural force in pharma M&A in 2026. Large-cap pharma companies are racing to rebuild pipelines through acquisitions, licensing deals and strategic partnerships before revenue losses materialise, creating sustained deal flow across biotech, CRO, CDMO and specialty pharma.
The patent cliff is driving increased M&A and licensing as pharma works to rebuild pipelines and offset future revenue losses. Licensing and partnership activity surged, with global upfront and milestone payments rising 63% as pharma and biotech leaned more heavily on collaborations to advance pipelines.
In the UK, the MHRA's post-Brexit regulatory pathway has created both autonomy from EU regulatory timelines and, in some cases, accelerated approval pathways that generate additional demand for UK-based regulatory and clinical services.
What Investors Are Targeting
Assets Attracting Capital in Pharma
Specialty Pharma
Asset-light specialty pharma businesses with proprietary products in niche therapeutic areas — particularly rare diseases, oncology and CNS — command strong strategic buyer interest. The patent cliff creates a structural M&A mandate that keeps deal multiples elevated for differentiated assets.
CROs and CDMOs
Contract research and manufacturing organisations benefiting from outsourcing growth. Pharma services remain one of the largest private equity market segments in healthcare, driven by recurring revenue characteristics, low capital intensity relative to drug development and the structural trend toward outsourcing.
Biosimilars
The biosimilar market is expanding as original biologic patents expire, creating investment opportunities in manufacturing platforms, regulatory approval specialists and commercial-stage biosimilar portfolios.
Key Risks
Risks for Pharma Investors in 2026
- US drug pricing policy creating uncertainty for pharmaceutical company revenue forecasts
- NHS NICE approval processes and pricing negotiations creating UK market access risk
- Patent cliff timing: revenue losses accelerate before pipeline assets generate replacement revenues
- AI drug discovery shortening competitive moats for traditional pharmaceutical R&D
Subscribe
Stay Informed on Healthcare Investment
Subscribe to Healthcare Investor Magazine — independent investment intelligence for investors, family offices and private wealth owners.
FAQs
Frequently Asked Questions
Related Sectors
Explore Other Investment Sectors
Published for informational purposes only. Does not constitute financial or investment advice. All data sourced from primary institutional sources as cited. Seek independent professional advice before making any investment decision.